Skip to main content
Caplight Logo









Symbiosis C.M.

Symbiosis C.M.

Private
IsraelHealthcare & Life Scienceshttps://symbiosis-cm.com/

Last Round

Grant

Oct 29, 2024

Total Funding Raised

$4.1M

Company Overview

Symbiosis C.M. is a medical device company that develops adaptive transcatheter heart valve technology for the treatment of mitral regurgitation.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

transcatheter heart valvemitral regurgitationTMVRtranscatheter mitral valve replacementminimally invasive surgerycardiovascular medical deviceinterventional cardiologyheart valve replacementmedtechcardiac implantstructural heartclinical trials

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Symbiosis C.M. Comparables

Compare Symbiosis C.M. with similar companies based on industry and business-model similarity.

Symbiosis C.M. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tioga Cardiovascular
86%
ReValve Solutions
83%
4C Medical Technologies, Inc.
83%

Symbiosis C.M. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 29, 2024
GrantMay 1, 2024
SeedDec 1, 2023
Pre SeedJan 1, 2023
GrantJul 22, 2022
Angel
Jan 1, 2022

Symbiosis C.M. Investors

Notable investors and investment history

Symbiosis C.M. investors
InvestorRounds
Coller CapitalGrant
Israel Innovation AuthorityGrant, Angel
The Jon DeHaan FoundationGrant
Jeremy Coller FoundationPre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 2, 2025

    Grew 21% QoQ from 14 to 17 employees.

  • Feb 25, 2025

    Grew 56% QoQ, from 9 to 14 employees.

Symbiosis C.M. Filings

Explore SEC and related filing metadata, where available.

Symbiosis C.M. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Symbiosis C.M.'s valuation, stock price, and market status.

Is Symbiosis C.M. a public or private company?

Symbiosis C.M. is a private company.

What is the current stock price of Symbiosis C.M.?

Symbiosis C.M. is a private company with no public stock price. No recent secondary market data is available.

How much is Symbiosis C.M. worth (valuation)?

Valuation information for Symbiosis C.M. is not publicly available.

Can I buy Symbiosis C.M. stock?

Symbiosis C.M. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Symbiosis C.M.'s last funding round?

Symbiosis C.M.'s most recent funding round was Grant on October 27, 2024.

Who are the main investors in Symbiosis C.M.?

Key investors in Symbiosis C.M. include Coller Capital, Israel Innovation Authority, The Jon DeHaan Foundation.

Will Symbiosis C.M. IPO soon?

No public IPO plans have been announced for Symbiosis C.M..

How can I track Symbiosis C.M. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Symbiosis C.M.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersIsrael
Employee Range18
Year Founded2021
Last FundingOct 29, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?